MINAPHARM Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Wafik El Bardissi

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.8%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Wafik El Bardissi

no data

테뉴어

Dr. Wafik Saad El Bardissi serves as the Executive Chairman and Chief Executive Officer at Minapharm Pharmaceuticals SAE. Dr. El Bardissi has been working in the pharmaceutical and biopharmaceutical indust...

MINAPHARM Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

No independent directors

No independent directors

Recent updates

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)

New minor risk - Financial data availability

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)

Upcoming dividend of ج.م2.80 per share at 1.3% yield

First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)

Investor sentiment improves as stock rises 15%

Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Upcoming dividend of ج.م2.92 per share

Investor sentiment improved over the past week

No independent directors

Investor sentiment improved over the past week

Upcoming dividend of ج.م2.70 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2020 earnings released

Investor sentiment improved over the past week

New 90-day high: ج.م86.57

New 90-day high: ج.م85.89

Third quarter 2020 earnings released: EPS ج.م6.32

New 90-day high: ج.م80.50

First half earnings released

Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.

CEO

테뉴어